Treatment

GFH375, an experimental oral drug, is showing promising results for patients with advanced KRAS G12D–mutant pancreatic cancer, a mutation present in roughly 40% of pancreatic ductal adenocarcinomas. The early-phase trial involved daily 600 mg doses in patients who had already received multiple treatments. The therapy produced tumor shrinkage in 40.7% of patients, all partial responses, and […]

The phase 3 KEYNOTE-B96/ENGOT-ov65 trial (NCT05116189) showed that combining pembrolizumab (Keytruda) with weekly paclitaxel—with or without bevacizumab (Avastin)—improves survival in patients with platinum-resistant recurrent ovarian cancer (PROC). This is the first immune checkpoint inhibitor regimen to demonstrate a significant overall survival benefit in this setting. In 643 patients, the treatment improved median progression-free survival (PFS)

A new study points to the protein TRIM21 as a key driver of pancreatic adenocarcinoma (PAAD), one of the deadliest cancers with a 5-year survival rate below 9%. Using bioinformatics and lab experiments, researchers found that TRIM21 is highly overexpressed in pancreatic cancer tissues and strongly linked to poor patient outcomes. High levels of TRIM21

Researchers have developed a simple, cost-effective test to classify BRAF V600E–mutant colorectal cancer (CRC), advancing personalized therapy. The new immunohistochemistry (IHC)–based system, called iBM, uses two protein markers—CD8, indicating immune activity, and ARHGEF17, involved in cell-cycle regulation—to identify tumor subtypes without expensive genomic sequencing. The test categorizes tumors into two groups: iBM1, with high immune

Pirtobrutinib is a new therapy for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), especially in patients who have received multiple prior treatments. Unlike older BTK inhibitors, pirtobrutinib is a selective, noncovalent BTK inhibitor that binds reversibly and remains effective against the common C481S mutation causing resistance. In the Phase 1/2 BRUIN trial, it achieved an

The updated results from the Phase III TOPAZ-1 trial, with a median follow-up of about 41 months, provide the longest data yet for durvalumab combined with gemcitabine and cisplatin in advanced biliary tract cancer. The study continues to show a strong and lasting survival benefit for patients receiving the immunotherapy combination compared to standard chemotherapy

Metastatic pancreatic cancer treatment is increasingly personalized, considering tumor biology, patient health, and treatment goals. Assessing comorbidities, nutrition, and performance status helps guide therapy intensity, while molecular testing—including BRCA and RAS mutations—identifies actionable targets. The FDA-approved NALIRIFOX regimen (liposomal irinotecan, oxaliplatin, 5-FU, leucovorin) demonstrated improved outcomes over gemcitabine plus nab-paclitaxel in the NAPOLI 3 trial. Compared

Pembrolizumab (Keytruda) has been approved for use before and after surgery in adults with resectable, locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 (CPS ≥1). The treatment plan includes pembrolizumab alone before surgery, followed by pembrolizumab with standard radiation therapy (with or without cisplatin) after surgery, and continued pembrolizumab afterward.

The phase 1 FORAGER-1 trial tested vepugratinib (LY3866288), a selective oral FGFR3 inhibitor, in metastatic urothelial carcinoma (mUC) patients with FGFR3 alterations (15–20% of cases). Unlike older pan-FGFR inhibitors, vepugratinib targets FGFR3 specifically to reduce off-target toxicity. As a single agent, 200 mg twice daily showed the best balance of efficacy and safety, producing a 34% overall

A new combination of darovasertib and crizotinib shows remarkable promise for metastatic uveal melanoma (MUM), a historically hard-to-treat eye cancer. In the Phase 1/2 OptimUM-01 trial, patients receiving this therapy lived a median of 21.1 months—nearly double the usual survival—and went about seven months without disease progression, more than twice the expected duration. The treatment achieved a